Reply: Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia

Ali McBride, Kim Campbell, Mohan Bikkina, Karen MacDonald, Ivo Abraham, Sanjeev Balu

Research output: Contribution to journalLetter

1 Scopus citations
Original languageEnglish (US)
Pages (from-to)606-609
Number of pages4
JournalJournal of medical economics
Volume21
Issue number6
DOIs
StatePublished - Jun 3 2018

ASJC Scopus subject areas

  • Health Policy

Cite this